Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Engage Therapeutics

Request full access

Inhaled drug-device for rapid epileptic seizure termination

United StatesFounded 2017Biotech & Life Sciences

About Engage Therapeutics

Engage Therapeutics, Inc. was a clinical-stage biopharmaceutical company founded in 2017 by Greg Mayes and Jouko Isojarvi. The company focused on developing a rescue therapy for individuals experiencing uncontrolled epileptic seizures. Several of the company's founders and leaders had personal connections to epilepsy, driving their commitment to the field.

The company's main product was Staccato® alprazolam, a drug-device combination designed for the rapid termination of an active epileptic seizure, a condition known as Rapid Epileptic Seizure Termination (REST). This product consists of a small, hand-held inhaler that delivers the FDA-approved benzodiazepine, alprazolam. The Staccato® system works by rapidly vaporizing the drug into an aerosol with a particle size suitable for deep lung delivery, enabling a quick systemic effect. Clinical trial results showed it could stop seizure activity within two minutes of administration without recurrence within two hours. Engage Therapeutics acquired the worldwide rights to Staccato® alprazolam through an exclusive license and supply agreement with Alexza Pharmaceuticals in 2017.

The company's business model was centered on the clinical development and potential commercialization of this novel therapy, pursuing a 505(b)(2) regulatory pathway. It successfully raised $30.6 million in funding over two rounds from investors including TPG Biotech, Adage Capital Management, and Lumira Ventures. On June 5, 2020, Engage Therapeutics was acquired by UCB, a global biopharmaceutical company, for an initial payment of $125 million, with potential future milestone payments of up to $145 million. Following the acquisition, Engage Therapeutics became a wholly-owned subsidiary of UCB, which continues the development of Staccato® alprazolam.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
United States
Open positions
None listed
Dealroom signal
19.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Epilepsy, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2017 $24M $94M Granite Point Capital · Lumira Ventures · TPG · TPG Biotech —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Engage Therapeutics website traffic

Latest recorded traffic for Engage Therapeutics is 220 monthly website visits.

Latest monthly visits220
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Engage Therapeutics in its local ecosystem

Live from Dealroom

The Engage Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • TPG
  • Granite Point Capital
  • Lumira Ventures
  • TPG Biotech
  • Adage Capital

Other known investors1 additional known investor

  • LifeSci Venture Partners
Team profiled 128 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Engage Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Engage Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.